DNA | Jotup

EQS-News: Shelly Group accelerates expansion into professional market segments using globally established hardware and software standards

Retrieved on:

星期三, 四月 10, 2024

Automation, Heat, Light, Internet of things, Installation (computer programs), Air conditioning, Ventilation, DNA, Light + Building, KNX, Lighting, Ticker

Sofia / Munich, 13 March 2024 – Shelly Group AD (Ticker: SLYG / ISIN: BG1100003166 ) (“Shelly Group” / “the Company“), a provider of IoT and smart building solutions based in Sofia, Bulgaria, is accelerating its expansion into professional market segments.

Key Points:

Sofia / Munich, 13 March 2024 – Shelly Group AD (Ticker: SLYG / ISIN: BG1100003166 ) (“Shelly Group” / “the Company“), a provider of IoT and smart building solutions based in Sofia, Bulgaria, is accelerating its expansion into professional market segments.
To this end, Shelly announced the integration of globally established hardware and software standards at Light + Building 2024, the world's leading expo for lighting and building technology.
In addition, Shelly is launching a new free tool that connects end customers in the German market with electricians for the installation of their products.
In this way, we increase customer and professional user loyalty and strengthen our market penetration and competitive position.“

EQS-News: ProCredit group reaches key milestones in its comprehensive sustainability strategy in 2023 and defines further targets

Retrieved on:

星期三, 四月 10, 2024

With the inauguration of our own “ProEnergy” solar park to the electricity grid in Kosovo in July 2023, the ProCredit group took an important step towards achieving climate neutrality.

Key Points:

With the inauguration of our own “ProEnergy” solar park to the electricity grid in Kosovo in July 2023, the ProCredit group took an important step towards achieving climate neutrality.
A number of other initiatives contributed to the reduction of ProCredit’s ecological footprint in 2023 and thus reinforced the group’s sustainability strategy.
Furthermore, the ProCredit group was able to maintain its 100% recycling rate for paper waste and electronic waste in 2023.
The Impact Report Package 2023 of the ProCredit group as well as the Annual Report 2023 are available as of today on the ProCredit Holding website in the Investor Relations section at:

Concept2048 Unveils "Whisper of the Sea" at the Personal Structures Exhibition During the Venice Art Biennale 2024

Retrieved on:

星期一, 三月 25, 2024

Perekopskaya, Palazzo Bembo, Conscience, Environment, Venice Biennale, DNA, Human, Rialto Bridge, Beyond Boundaries, Sea, Exhibition, Heart, Grand Canal, Personal Structures, European, Entertainment

This immersive exhibition, part of the 7th edition of the Personal Structures exhibition, organised by the European Cultural Centre, held during the 60th Venice Art Biennale, runs from April 20 to November 24, 2024.

Key Points:

This immersive exhibition, part of the 7th edition of the Personal Structures exhibition, organised by the European Cultural Centre, held during the 60th Venice Art Biennale, runs from April 20 to November 24, 2024.
It intertwines mythical narratives with urgent global concerns, showcasing the duo's innovative fusion of contemporary art, activism, and multimedia storytelling.
The theme of this year's Personal Structures exhibition "Beyond Boundaries," perfectly aligns with the concept of "Whisper of the Sea".
Ekaterina Perekopskaya and Rostyslav Brenych, the creative force behind Concept2048, craft a multisensory journey with "Whisper of the Sea."

Halcon Marketing Solutions Launches New Service Offerings Amidst a Post-Pandemic Economic Boon

Retrieved on:

星期二, 四月 2, 2024

MTV, Certification, COVID, Social media, DNA, Neuroscience, Psychology, Marketing, Fox Entertainment Group, Cognitive science, Paramount Network, Asset management

St. Louis, Missouri--(Newsfile Corp. - April 2, 2024) - HALCON Marketing Solutions , founded by Nicole Powell , has achieved certification in Neuromarketing, an innovative discipline merging neuroscience and cognitive science with marketing strategies.

Key Points:

St. Louis, Missouri--(Newsfile Corp. - April 2, 2024) - HALCON Marketing Solutions , founded by Nicole Powell , has achieved certification in Neuromarketing, an innovative discipline merging neuroscience and cognitive science with marketing strategies.
This certification allows the company to unveil new services tailored to navigating the complexities of post-COVID sales.
This comprehensive approach empowers clients to develop finely tuned marketing strategies that effectively adapt to consumers' evolving preferences.
In addition, HALCON provides a suite of marketing services that span brand strategy, social media management, email marketing, design, content creation, web development, and strategic branding.

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on:

星期三, 三月 13, 2024

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points:

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
To view an enhanced version of this graphic, please visit:
The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on:

星期二, 四月 9, 2024

MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points:

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
“Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

Eurofins Genomics AgriGenomics Europe and Gencove announce collaboration to offer complete solution for low-pass whole genome sequencing

Retrieved on:

星期二, 四月 9, 2024

Agriculture, Partnership, DNA, SNP, Doctor of Philosophy, Genomics, Aquaculture, Antibiotics

New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.

Key Points:

New York, USA and Galten, Denmark, April 09, 2024 (GLOBE NEWSWIRE) -- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services and Gencove, a pioneer of low-pass whole genome sequencing (lpWGS) imputation and analysis, today announced a partnership to offer a complete solution for lpWGS in Europe, delivering high-throughput and cost-effective sequencing.
The partnership will combine Gencove’s platform for data analytics and management with Eurofins Genomics AgriGenomics Europe’s capabilities running low-pass whole genomics sequencing to usher in a new era in genotyping.
The collaboration leverages both companies' strengths in sequencing to accelerate advancements in genotyping benefiting plant breeders, livestock selectors, aquaculture, and companion animal sectors.
In making large-scale genomic information more accessible and actionable, Gencove and Eurofins Genomics AgriGenomics Europe are setting new benchmarks for what is possible in agriculture.

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on:

星期二, 四月 9, 2024

Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points:

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Retrieved on:

星期二, 四月 9, 2024

Epigenomics, EGFR, NSCLC, Patient, DNA, Messenger, Lung cancer, Therapy, MYC

Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller

Key Points:

Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10.
The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate, OTX-2002.
“We’re excited to share these preclinical data at this year’s AACR Annual Meeting, which continue to validate Omega’s platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
“These results further underscore the tremendous potential for a MYC-directed epigenomic controller as a novel orthogonal treatment strategy for non-small cell lung cancer as a monotherapy and in combination with existing therapies.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Retrieved on:

星期一, 四月 8, 2024

Euronext Growth, Gene, DNA, HSPC, Society, Therapy, Cell, Gene editing, Vaccine

Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).

Key Points:

Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).
Gene therapy using hematopoietic and progenitor stem cells (HSPC) has the potential to provide a lifelong supply of genetically encoded therapeutics.
Gene editing strategies enabling supra-endogenous expression of therapeutics often rely on constitutive promoters resulting in transgene overexpression irrespective of cellular differentiation, which could be detrimental for HSPC function.
Full abstracts and presentations will be available on Cellectis’ website following the event: